MIBI-THYR : Value of the combination ultrasonography with Ti-RADS score / dual tracer scintigraphy MIBI-Tc99m/Iodine-123 in the detection of malignancy of thyroid nodules (≥15 mm) classified Bethesda III or IV on cytology

2024-516416-22-00 Protocol RC18_0052 Phase II and Phase III (Integrated) Ended

Start 17 Jan 2019 · End 7 May 2025 · Status Ended · 1 EU/EEA countries · 5 sites · Protocol RC18_0052

Overview

Sponsor-declared trial summary

Phase Phase II and Phase III (Integrated)
Status Ended
Participants planned 375
Countries 1
Sites 5

malignancy of thyroid nodules

Key facts

Sponsor
Centre Hospitalier Universitaire De Nantes
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Hormonal diseases [C19]
Trial duration
17 Jan 2019 → 7 May 2025
Decision date (initial)
2024-10-07
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-516416-22-00
EudraCT number
2018-001960-45
ClinicalTrials.gov
NCT03498183

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

malignancy of thyroid nodules

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Hospitalier Universitaire De Nantes

Sponsor organisation
Centre Hospitalier Universitaire De Nantes
Address
5 Allee De L Ile Gloriette, Cs 69301 Cs 69301
City
Nantes Cedex 1
Postcode
44093
Country
France

Scientific contact point

Organisation
Centre Hospitalier Universitaire De Nantes
Contact name
Eric MIRALLIE

Public contact point

Organisation
Centre Hospitalier Universitaire De Nantes
Contact name
Eric MIRALLIE

Locations

1 EU/EEA country · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 375 5
Rest of world 0

Investigational sites

France

5 sites · Ended
Institut Curie
nuclear medecine, 26 Rue D Ulm, 75005, Paris
Centre Hospitalier Universitaire De Lille
Endocrinology, 2 Avenue Oscar Lambret, Cs 70001, Lille Cedex
CHRU De Nancy
endocrinology, 11 Rue Du Morvan, Bp 80001, Vandoeuvre Les Nancy Cedex
Centre Hospitalier Universitaire De Nantes
Endocrinology, 5 Allee De L Ile Gloriette, Cs 69301, Nantes Cedex 1
Hospices Civils De Lyon
Endocrinology, 165 Chemin Du Grand Revoyet, 69310, Pierre Benite

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2019-01-17 2025-05-07 2019-01-17 2024-07-17

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-30 France Acceptable
2024-09-16
2024-10-07